Last updated: September 26, 2026
CAMPTOSAR is the original branded formulation of irinotecan hydrochloride, a topoisomerase I inhibitor used primarily in colorectal cancer. Its commercial trajectory has moved from premium branded oncology sales to mature, multisource generic competition. The principal financial issue is no longer patent protection. It is utilization of irinotecan-containing regimens, hospital purchasing, generic price erosion, and competition from newer colorectal and pancreatic cancer therapies.
Pfizer does not report CAMPTOSAR revenue as a standalone product in its current public financial disclosures. The brand’s direct commercial contribution is therefore not separately measurable from Pfizer filings. The economic value of irinotecan remains significant at the treatment-class level, but most current volume is supplied through generic irinotecan injection rather than the CAMPTOSAR brand.
What is CAMPTOSAR and how is irinotecan used?
CAMPTOSAR contains irinotecan hydrochloride, a topoisomerase I inhibitor administered by intravenous infusion. The FDA-approved product is used in combination with 5-fluorouracil and leucovorin, or as a single agent, for metastatic colorectal cancer under specified treatment settings.[1]
| Attribute |
CAMPTOSAR |
| Active ingredient |
Irinotecan hydrochloride |
| Drug class |
Topoisomerase I inhibitor |
| Route |
Intravenous infusion |
| Original developer |
Pharmacia |
| Current historical owner |
Pfizer, following Pfizer’s acquisition of Pharmacia |
| Primary US indication |
Metastatic colorectal cancer |
| FDA application |
NDA 020571 |
| Commercial status |
Mature branded product with generic competition |
| Principal generic form |
Irinotecan hydrochloride injection |
| Biosimilar exposure |
None, because irinotecan is a small-molecule drug |
Irinotecan is commonly used in FOLFIRI, a regimen combining irinotecan with 5-fluorouracil and leucovorin. It also appears in modified colorectal cancer protocols and in combination regimens selected according to tumor biology, prior treatment, patient performance status, and toxicity risk.
The active metabolite SN-38 is responsible for much of irinotecan’s antitumor activity. UGT1A1-mediated glucuronidation affects SN-38 exposure and can influence neutropenia and diarrhea risk. The pharmacogenomic relationship is clinically relevant, but it has not created a durable commercial barrier around the CAMPTOSAR brand.
When did CAMPTOSAR lose market exclusivity?
CAMPTOSAR’s principal commercial exclusivity ended years ago. Irinotecan injection is now a mature generic category with multiple suppliers and no meaningful US composition-of-matter exclusivity protecting the original brand.
The product was approved in the United States in 1996. Its commercial protection developed through the original composition and formulation patent estate, regulatory exclusivity, and oncology labeling. Those protections expired before the current market period, allowing generic irinotecan hydrochloride injections to enter the US market.
| Milestone |
Approximate timing |
Commercial effect |
| US FDA approval of CAMPTOSAR |
1996 |
Initiated branded colorectal cancer sales |
| Pharmacia ownership period |
1990s to 2003 |
Established the original oncology franchise |
| Pfizer acquisition of Pharmacia |
2003 |
Transferred CAMPTOSAR to Pfizer |
| Generic irinotecan competition |
2000s onward |
Reduced brand pricing power and share |
| Current market |
2020s |
Generic-dominated injectable market |
The exact commercial decline cannot be reconstructed from Pfizer’s current annual reports because CAMPTOSAR is not disclosed as a separate reporting unit. Pfizer reports operating segments and selected product revenues, but not a current standalone CAMPTOSAR revenue line.[2]
What patents protect CAMPTOSAR?
The original CAMPTOSAR patent estate protected irinotecan chemistry and, in some jurisdictions, pharmaceutical compositions or therapeutic uses. Those core rights are expired or commercially exhausted in the United States.
What is the Orange Book status of CAMPTOSAR?
The FDA Orange Book remains the relevant US source for listed patents, approved dosage forms, and generic-equivalence information.[3] For a product with longstanding generic competition, the commercial question is whether any unexpired, enforceable patent remains capable of blocking an ANDA. For CAMPTOSAR, the historical composition and formulation rights do not provide a current barrier comparable with a newly launched oncology drug.
The absence of a current patent barrier has several consequences:
- Generic manufacturers can compete through abbreviated new drug applications.
- Purchasers can substitute generic irinotecan injection under institutional formularies.
- Pfizer has limited ability to preserve a premium solely through the original CAMPTOSAR trademark.
- Any residual brand demand is driven by prescribing familiarity, supply reliability, contracting, and institutional preference.
Are there formulation patents for CAMPTOSAR?
The conventional CAMPTOSAR formulation is an injectable irinotecan solution. Formulation protection has less commercial value after generic approval because the principal product is a standard hospital-administered injectable rather than a differentiated delivery system.
Irinotecan-based products with different delivery technologies, including liposomal irinotecan, are legally and commercially distinct. Onivyde, a liposomal irinotecan product marketed by Ipsen, is not a generic version of CAMPTOSAR. It has its own formulation, clinical labeling, patent estate, and pricing structure.[4]
Are there Paragraph IV challenges to CAMPTOSAR?
Paragraph IV litigation is not a central current risk for CAMPTOSAR because the product’s core market exclusivity has already expired and generic irinotecan products have long been available.
A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or not infringed. That mechanism is most important when a branded drug still has active Orange Book patents that could delay generic entry. For CAMPTOSAR, the relevant competitive event was the historical transition to generic irinotecan, not a pending first-wave Paragraph IV challenge.
Current generic competition is therefore better analyzed through:
- The number of approved irinotecan injection suppliers.
- Manufacturing reliability and shortage exposure.
- Contracting with hospitals and group purchasing organizations.
- Concentration among sterile injectable manufacturers.
- Substitution policies and reimbursement spreads.
How strong is the CAMPTOSAR patent estate?
The current CAMPTOSAR patent estate is weak as a commercial exclusion tool but still relevant for historical patent analysis.
| Patent-estate factor |
Current assessment |
| Original molecule protection |
Expired |
| Core US market exclusivity |
Expired |
| Generic substitution |
Established |
| Reformulation protection |
Limited relevance to conventional injection |
| Method-of-use exclusivity |
No material current barrier identified for the core colorectal indications |
| Biosimilar protection |
Not applicable |
| Litigation leverage |
Low compared with actively protected oncology products |
| Manufacturing know-how |
Relevant to quality and supply, but not a substitute for patent exclusivity |
Manufacturing can still create operational barriers. Irinotecan is a sterile injectable, and production requires validated aseptic processing, quality systems, regulatory approval, and dependable active pharmaceutical ingredient supply. These requirements can limit the number of reliable suppliers even when patent protection has ended.
That barrier is economic and regulatory rather than exclusivity-based.
How has CAMPTOSAR’s financial trajectory changed?
CAMPTOSAR’s financial trajectory follows the standard lifecycle of a first-generation oncology product:
Branded growth phase
During the late 1990s and early 2000s, irinotecan benefited from increasing use in metastatic colorectal cancer and adoption of combination chemotherapy. The product was sold at branded oncology pricing and supported by the clinical expansion of irinotecan-containing regimens.
Ownership transition
Pfizer acquired Pharmacia in 2003. CAMPTOSAR became part of Pfizer’s broader oncology portfolio. The acquisition increased Pfizer’s scale but did not create a new exclusivity cycle for irinotecan.[2]
Generic erosion
Once generic irinotecan became available, the brand faced price pressure and institutional substitution. In injectable oncology, generic entry can reduce both unit price and branded volume because hospitals often purchase through competitive contracts.
Mature generic phase
The current value pool is concentrated in generic irinotecan utilization. Brand revenue is constrained by:
- Generic substitution.
- Hospital and oncology-center purchasing.
- Reimbursement based on acquisition cost or average sales price.
- Treatment movement toward targeted agents and immunotherapies.
- Regimen selection based on molecular testing and patient fitness.
- Competition from oxaliplatin-based, oral fluoropyrimidine, anti-VEGF, anti-EGFR, BRAF-directed, HER2-directed, and immune-oncology approaches.
Pfizer’s public reporting does not provide a current CAMPTOSAR revenue figure. Any precise estimate of annual brand sales would require third-party prescription, shipment, or claims data and should not be inferred from Pfizer’s consolidated oncology revenue.
What companies compete with CAMPTOSAR?
Competition exists at both the product and regimen levels.
Generic irinotecan suppliers
The US market has included generic injectable suppliers such as Teva, Fresenius Kabi, Hikma, and other approved manufacturers over time. Supplier participation can change because of manufacturing economics, shortages, site transfers, and product discontinuations. The relevant competitor is often not another branded irinotecan product but the lowest-cost approved sterile injectable supplier.
Onivyde
Onivyde is a liposomal irinotecan formulation marketed by Ipsen. It is used in pancreatic cancer combinations and is not therapeutically interchangeable with conventional irinotecan injection. Its differentiated delivery system and clinical positioning support a separate pricing model.[4]
Alternative colorectal cancer therapies
CAMPTOSAR competes indirectly with:
- Oxaliplatin-based regimens such as FOLFOX.
- Trifluridine/tipiracil.
- Regorafenib.
- Bevacizumab-containing regimens.
- Cetuximab or panitumumab in selected RAS-wild-type tumors.
- BRAF-directed combinations for BRAF V600E disease.
- HER2-directed therapy for selected HER2-positive tumors.
- Pembrolizumab or nivolumab-based approaches in eligible microsatellite instability-high or mismatch-repair-deficient tumors.
The competitive effect is not uniform. Irinotecan remains embedded in established chemotherapy pathways, especially FOLFIRI, but the addressable population changes as biomarker-directed treatment expands.
What generic launch risks exist for CAMPTOSAR?
The principal generic launch risk has already occurred. Future commercial risks relate to supply and price rather than a new loss of exclusivity event.
Generic pricing risk
Multiple approved suppliers generally reduce average selling prices. Injectable generics may experience rapid price erosion when capacity exceeds demand, although shortages can temporarily reverse that trend.
Supply-chain risk
Sterile injectable manufacturing is vulnerable to plant quality actions, raw-material constraints, production interruptions, and limited supplier redundancy. A supply disruption can increase short-term demand for the remaining suppliers and create temporary price volatility.
Clinical substitution risk
Hospitals can substitute approved generic irinotecan for CAMPTOSAR when the concentration, dosage form, and labeling support substitution under applicable institutional and state rules.
Regimen displacement risk
The larger long-term risk is reduced use of irinotecan-based chemotherapy in segments where targeted or immune therapies move earlier in the treatment pathway. This risk is strongest in biomarker-defined colorectal cancer populations and weaker in settings where cytotoxic chemotherapy remains foundational.
What is the geographic coverage of CAMPTOSAR and generic irinotecan?
CAMPTOSAR was commercialized across major oncology markets, but current geographic economics differ materially.
| Region |
Market condition |
| United States |
Mature generic competition; hospital purchasing and injectable supply are central |
| European Union |
Country-specific reimbursement and procurement; generic irinotecan widely available |
| Japan |
Established irinotecan use with local reimbursement and manufacturer dynamics |
| Emerging markets |
Greater variation in branded and generic availability, pricing, and regulatory standards |
Patent expiry generally creates the legal opportunity for generic entry, but actual entry depends on local approval, pricing, reimbursement, procurement, and manufacturing economics. A US patent conclusion does not establish equivalent entry timing in Europe, Japan, China, or other markets.
What litigation and settlement agreements affect CAMPTOSAR?
No current high-value litigation or settlement agreement is required to explain CAMPTOSAR’s market position. The decisive legal event was the expiration of core exclusivity and the resulting availability of generic irinotecan.
For current diligence, the relevant checks are:
- FDA Orange Book listings for NDA 020571.
- FDA Drugs@FDA approval history.
- ANDA approvals for irinotecan hydrochloride injection.
- Federal court records for any later formulation or labeling disputes.
- Product-specific discontinuation and shortage notices.
- Pfizer disclosures concerning legacy oncology products.
The litigation profile is materially lower than for newer oncology products with active composition, formulation, or method-of-use patents.
What is the FDA regulatory status of CAMPTOSAR?
CAMPTOSAR is an FDA-approved conventional irinotecan injection product. Generic irinotecan hydrochloride injections are approved through the ANDA pathway when they meet applicable requirements for pharmaceutical equivalence and bioequivalence.[1,3]
Irinotecan does not have biosimilar competition because biosimilars apply to biological products. Its competitive pathway is generic small-molecule approval, not the abbreviated biologics pathway.
How does CAMPTOSAR compare with Onivyde?
| Category |
CAMPTOSAR |
Onivyde |
| Active drug |
Conventional irinotecan |
Liposomal irinotecan |
| Delivery technology |
Standard injectable solution |
Liposomal nanoparticle formulation |
| Main commercial role |
Colorectal cancer chemotherapy |
Pancreatic cancer combination therapy and other labeled uses |
| Substitution |
Generic irinotecan substitutes available |
Not interchangeable with conventional irinotecan |
| Patent profile |
Mature, largely expired estate |
Separate active formulation and use protections may apply |
| Pricing model |
Generic and institutionally negotiated |
Branded specialty oncology pricing |
| Manufacturer |
Pfizer legacy brand |
Ipsen |
Onivyde does not restore CAMPTOSAR’s exclusivity. It represents a separate product strategy based on formulation differentiation and clinical positioning.
Key Takeaways
- CAMPTOSAR is the original branded irinotecan hydrochloride injection.
- Its core US exclusivity expired, and generic irinotecan is the dominant commercial supply.
- Pfizer does not separately disclose current CAMPTOSAR revenue.
- The brand’s direct financial contribution is likely limited relative to its historical peak, but the irinotecan treatment class remains clinically important.
- Current market risk is driven by generic pricing, sterile-injectable supply, and regimen displacement.
- There is no biosimilar issue because irinotecan is a small-molecule drug.
- Onivyde is a differentiated liposomal irinotecan product, not a CAMPTOSAR generic.
- The current CAMPTOSAR patent estate has low exclusionary strength.
- Future value depends more on chemotherapy utilization and supply reliability than on patent litigation.
FAQs About CAMPTOSAR Market Exclusivity and Commercial Risk
Is CAMPTOSAR still sold by Pfizer?
CAMPTOSAR has historical Pfizer ownership, but Pfizer’s current public filings do not separately report a standalone CAMPTOSAR sales line. Generic irinotecan is the primary commercial alternative.
Can generic irinotecan replace CAMPTOSAR?
Generic irinotecan hydrochloride injection can generally compete with CAMPTOSAR when it has the same applicable strength, dosage form, route, and regulatory status. Institutional substitution depends on procurement and pharmacy policies.
Does CAMPTOSAR have patent protection for colorectal cancer use?
The original colorectal cancer patent protections are not a current practical barrier to generic irinotecan competition in the United States.
Is Onivyde a generic version of CAMPTOSAR?
No. Onivyde is a liposomal irinotecan formulation with separate clinical, regulatory, and intellectual-property characteristics.
What is the main investment risk associated with irinotecan?
The main risks are generic price erosion, reduced chemotherapy use in biomarker-selected populations, and manufacturing or supply interruptions affecting sterile injectable products.
References
-
U.S. Food and Drug Administration. (2024). CAMPTOSAR (irinotecan hydrochloride) injection prescribing information. FDA.
-
Pfizer Inc. (2004). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Pfizer Inc.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
Ipsen Biopharmaceuticals, Inc. (2024). ONIVYDE (irinotecan liposome injection) prescribing information. U.S. Food and Drug Administration.
